Form 4: EXACT Sciences Director Sells 2,000 Shares
Insider Transaction Report
EXACT Sciences Director James Edward Doyle sold 2,000 shares of common stock for $60 per share on October 9, 2025, pursuant to a pre-arranged 10b5-1 trading plan.
Summary
- James Edward Doyle, a Director of EXACT Sciences Corp (EXAS), reported a sale of common stock.
- The transaction involved the disposition of 2,000 shares of common stock.
- The sale occurred on October 9, 2025, at a price of $60 per share.
- Following this transaction, James Edward Doyle directly beneficially owns 57,962 shares of common stock.
- The sale was executed under a Rule 10b5-1 trading plan, which was established on March 9, 2025.
Sentiment
Score: 5
Explanation: The sentiment is neutral. The transaction is a pre-scheduled sale under a Rule 10b5-1 plan, indicating a non-discretionary personal financial planning event rather than a reaction to new company-specific information. This type of insider sale is generally not interpreted as a positive or negative signal for the company's fundamentals.
Future Outlook
The filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This insider transaction is a routine disclosure for a publicly traded company and does not inherently reflect broader industry trends or competitive positioning. It is a personal financial planning event for a director.
Stakeholder Impact
- Shareholders: The sale by a director, while pre-planned, represents a minor reduction in insider ownership. Given the 10b5-1 plan, it is unlikely to be interpreted as a negative signal regarding the company's future prospects.
Key Dates
| Date | Description |
|---|---|
| 03/09/2025 | Date Rule 10b5-1 trading plan was entered into by James Edward Doyle. |
| 10/09/2025 | Date of the reported transaction (sale of common stock). |
| 10/10/2025 | Date the Form 4 was signed by James Edward Doyle's attorney-in-fact. |
Recommendation
holdThe filing reports a pre-scheduled insider sale by a director, which is a routine event under a 10b5-1 plan and does not inherently signal a change in company fundamentals or future prospects. Therefore, it does not warrant a change in investment recommendation based solely on this transaction.
Keywords
EXAS, Exact Sciences, Form 4, Insider Trading, Stock Sale, Director, James Edward Doyle, 10b5-1 Plan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.